Targeted therapy for metastatic renal cell carcinoma
Referencias
Additional references
Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. Journal of Clinical Oncology 2005;23(23):5386‐403.
Bergsland EK. When does the presence of the target predict response to the targeted agent?. Journal of Clinical Oncology 2006;24(2):213‐6.
Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD001425.pub2]
National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS May 29th 2009:09‐7473.
Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105(7):2640‐53.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009;45(2):228‐47.
Fernández‐Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, et al. A systematic review and meta‐analysis comparing the effectiveness and adverse effects of different systemic treatments for non‐clear cell renal cell carcinoma. European Urology 2017;71(3):426‐43.
Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, et al. Interferon gamma‐1b compared with placebo in metastatic renal‐cell carcinoma. New England Journal of Medicine 1998;338(18):1265‐71.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide 2012. Available from globocan.iarc.fr (accessed 16 March 2015).
Evidence Prime Inc. GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University, 2015.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Alonso‐Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical Research Ed.) 2008;336(7650):924‐6.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94.
Hacker KE, Rathmell WK. Emerging molecular classification in renal cell carcinoma: implications for drug development. Targeted Oncology 2010;5(2):75‐84.
Hart B, Lundh A, Bero L. Effect of reporting bias on meta‐analyses of drug trials: reanalysis of meta‐analyses. BMJ 2012;344:d7202.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. [DOI: 10.1002/sim.1186]
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557‐60. [DOI: 10.1136/bmj.327.7414.557]
Higgins JP, Thompson SG, Spiegelhalter DJ. A re‐evaluation of random‐effects meta‐analysis. Journal of the Royal Statistical Society. Series A, (Statistics in Society) 2009;172(1):137‐59.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al (eds). SEER Cancer Statistics Review, 1975‐2014. National Cancer Institute. Bethesda, MD,posted to the SEER web site, April 2017; Vol. seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission.
Johnson JR, Ning Y‐M, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the Food and Drug Adminstration experience. Journal of the National Cancer Institute 2011;103(8):636‐44.
Kaelin WG. Kidney cancer: now available in a new flavor. Cancer Cell 2008;14(6):423‐4.
Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles T, et al. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. Angiogenesis 2017;20(2):205.
Linehan WM, Grubb RL, Coleman JA, Zbar B, Walther MM. The genetic basis of cancer of kidney cancer: implications for gene‐specific clinical management. BJU International 2005;95 Suppl 2:2‐7.
Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82. [DOI: 10.1186/2046‐4053‐3‐82]
Mickisch GHJ. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. European Urology 2003;43(6):670‐9.
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon‐alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of Clinical Oncology 2002;20(1):289‐96.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal‐cell carcinoma. New England Journal of Medicine 2015;373:1803‐13.
Oliver RTD, Nethersell ABW, Bottomly JM. Unexplained spontaneous regression and alpha‐interferon as treatment for metastatic renal carcinoma. British Journal of Urology 1989;63(2):128‐31.
Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and increasing proportion of favorable‐prognosis metastatic renal cell carcinoma patients. Cancer 2010;116(2):347‐54.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta‐analyses. BMJ 2011;342:d549.
Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor‐targeted therapy in renal cell carcinoma. Journal of Clinical Oncology 2005;23(5):1028‐43.
Roberts TG, Lynch TJ, Chabner BA. The phase III trial in the era of targeted therapy: unravelling the "go or no go" decision. Journal of Clinical Oncology 2003;21(19):3683‐95.
Sawyers C. Targeted cancer therapy. Nature 2004;432(7015):294‐7.
Schroll JB, Bero L. Regulatory agencies hold the key to improving Cochrane Reviews of drugs [editorial]. Cochrane Database of Systematic Reviews 2015;4:10:1002/14651858.ED000098.
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. American Journal of Surgical Pathology 2013;37(10):1469‐89.
Stadler W, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, et al. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimdazole ‐ CALBG 69901. Journal of Clinical Oncology 2005;23(16):3726‐32.
Stadler WM. New targets, therapies, and toxicities: lessons to be learned. Journal of Clinical Oncology 2006;24(1):4‐5.
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ 2011;343:d4002.
Strebhardt K, Ullrich A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Reviews Cancer 2008;8(6):473‐80.
Uzzo RG, Cairns P, Al‐Saleem T, Hudes G, Haas N, Greenberg RE, et al. The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician. Urologic Clinics of North America 2003;30(3):423‐36.
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ 2008;15;336(7644):601‐5.
Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clinical Cancer Research 2009;15(24):7582‐92.
References to other published versions of this review
Ir a:
Coppin C, Porzolt F, Le L, Autenrieth M, Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD006017]
Coppin C, Le L, Wilt TJ, Kollmannsberger C. Targeted therapy for advanced renal cell carcinoma. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD006017.pub2]
Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU International 2011;108(10):1556‐63.
| Axitinib |
| Bevacizumab |
| Dovitinib |
| Erlotinib |
| Everolimus |
| Lapatinib |
| Pazopanib |
| Sorafenib |
| Sunitinib |
| Temsirolimus |
| Thalidomide |
| Tivozanib |
| Other agents identified during search |
Figuras y tablas -
Table 1. Individual targeted agents to be searched
